| M John Hicks, MD | |
|
504 Medical Center Blvd, Conroe, TX 77304-2808 | |
| (713) 481-3544 | |
| (713) 432-0221 |
| Full Name | M John Hicks |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 36 Years |
| Location | 504 Medical Center Blvd, Conroe, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578568531 | NPI | - | NPPES |
| 117408801 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | J1685 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Childrens Hospital | 0244298446 | 17 |
News Archive
Results from a systematic review and meta-analysis show that erythrocyte membrane concentrations of certain polyunsaturated fatty acids are reduced in the brains of people with schizophrenia.
Tuberculosis (TB) is a major threat to global health, taking the lives of more than a million people worldwide each year. Its greatest impact is often in the most impoverished places on earth, where patients frequently suffer from multiple chronic illnesses at the same time. In such situations, the question of whether each individual illness might make concurrent illnesses more difficult to treat becomes a critical issue both for specific patients and for general public health.
Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.
Today, the U.S. Food and Drug Administration announced that an emergency use authorization has been issued for a rapid, single-use test for the detection of Ebola virus.
› Verified 3 days ago
| Entity Name | Texas Childrens Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487600334 PECOS PAC ID: 0244298446 Enrollment ID: O20041220000826 |
News Archive
Results from a systematic review and meta-analysis show that erythrocyte membrane concentrations of certain polyunsaturated fatty acids are reduced in the brains of people with schizophrenia.
Tuberculosis (TB) is a major threat to global health, taking the lives of more than a million people worldwide each year. Its greatest impact is often in the most impoverished places on earth, where patients frequently suffer from multiple chronic illnesses at the same time. In such situations, the question of whether each individual illness might make concurrent illnesses more difficult to treat becomes a critical issue both for specific patients and for general public health.
Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.
Today, the U.S. Food and Drug Administration announced that an emergency use authorization has been issued for a rapid, single-use test for the detection of Ebola virus.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| M John Hicks, MD Po Box 4677, Houston, TX 77210-4677 Ph: () - | M John Hicks, MD 504 Medical Center Blvd, Conroe, TX 77304-2808 Ph: (713) 481-3544 |
News Archive
Results from a systematic review and meta-analysis show that erythrocyte membrane concentrations of certain polyunsaturated fatty acids are reduced in the brains of people with schizophrenia.
Tuberculosis (TB) is a major threat to global health, taking the lives of more than a million people worldwide each year. Its greatest impact is often in the most impoverished places on earth, where patients frequently suffer from multiple chronic illnesses at the same time. In such situations, the question of whether each individual illness might make concurrent illnesses more difficult to treat becomes a critical issue both for specific patients and for general public health.
Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.
Today, the U.S. Food and Drug Administration announced that an emergency use authorization has been issued for a rapid, single-use test for the detection of Ebola virus.
› Verified 3 days ago
Michelle Hebert, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-432-1100 Fax: 713-432-0221 | |
Anne S. Witson, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 | |
Emilie Rouah, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 | |
Peter Allen Powaser, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 | |
Jacqueline Elizabeth Monheit, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 | |
David Houston Yawn, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 | |
Mary Ostrowski, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 504 Medical Center Blvd, Conroe, TX 77304 Phone: 713-481-3544 Fax: 713-432-0221 |